New immunotherapy combo targets rare cancers left behind by progress
NCT ID NCT06790706
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of rare advanced cancers that have not responded to standard treatment. The goal is to see if the combo can shrink tumors or stop them from growing. About 154 participants will be treated across 15 French centers, with each cancer type studied in its own group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HM, TIMONE Hospital, medical oncology department
NOT_YET_RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
AP-HP, Tenon Hospital, medical oncology department
NOT_YET_RECRUITINGParis, 75020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Eugène Marquis, medical oncology department
NOT_YET_RECRUITINGRennes, 35042, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Hospitalier Universitaire de Lille, medical oncology department
NOT_YET_RECRUITINGLille, 59037, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital
RECRUITINGLyon, 69003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital
RECRUITINGPierre-Bénite, 69310, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital
RECRUITINGBron, 69500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Insitut de Cancérologie Strasbourg Europe, medical oncology department
NOT_YET_RECRUITINGStrasbourg, 67200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Bergonié, medical oncology department
NOT_YET_RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Curie, thoracic oncology department
NOT_YET_RECRUITINGParis, 75005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Gustave Roussy, medical oncology department
NOT_YET_RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Paoli-Calmettes Marseille, medical oncology department
NOT_YET_RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Régional du Cancer de Montpellier, medical oncology department
NOT_YET_RECRUITINGMontpellier, 34298, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut de Cancerologie de l'Ouest , medical oncology department
NOT_YET_RECRUITINGAngers, 49055, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department
NOT_YET_RECRUITINGToulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
domvanalimab and zimberelimab (immunotherapy drugs)
What this could lead to
If successful, this could offer a new treatment option for people with rare advanced cancers that have stopped responding to standard therapy.
What could go wrong
This is an early phase II trial with small groups, so results may not apply broadly. The drugs can cause immune-related side effects, and the cancers are hard to treat.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.